Research records tagged for primary progressive MS (PPMS) or secondary progressive MS (SPMS). The page brings both groups together without assuming that a finding applies equally to each.
This hub updates as matching research records are published. AI-generated summaries are labelled when they have not yet been reviewed by a person.
AI
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 1/2Trial registry record – peer review not applicable
A Phase 1/2 interventional study involving 220 adults with various neurological autoimmune disorders, including progressive MS, was planned to evaluate the safety of CTX112. Participants were to be followed from the infusion up to 24 months, but no results have been posted yet.
What this does not proveNo results are posted, and planned enrollment and endpoints do not indicate outcomes or findings of the study.
A phase 3 study involving 156 adults with relapsing MS is ongoing, comparing autologous hematopoietic stem cell transplantation to the best available therapy. The primary endpoint is MS relapse-free survival, with follow-up extending up to 72 months. However, no results from this study have been posted thus far.
What this does not proveThe study does not provide any results, limiting the ability to assess its effectiveness or safety at this time.
This observational study is planned to assess how many patients with relapsing multiple sclerosis continue and adhere to ofatumumab treatment over time, with a target of about 5000 participants. Follow-up will occur at 6 months, 12 months, and up to 4 years, but no results are currently available as they have not been reported.
What this does not proveNo results are posted, and the study's planned enrollment and endpoints do not constitute findings.
The systematic review found that tolebrutinib significantly reduced the risk of confirmed disability progression in patients with secondary progressive multiple sclerosis (SPMS) and relapsing MS. Specifically, 18.35% risk reduction was observed at ≥3 months and 14.08% at ≥6 months. However, adverse events were common, occurring in about 76% of patients, though most were not serious.
What this does not proveThe findings are preliminary and not definitive; further research is required to confirm longevity and safety of tolebrutinib compared to existing therapies, and longer-term studies are essential.
A review of 27 studies on 1,317 individuals with multiple sclerosis (MS) assessed the prevalence of sudomotor dysfunction. Findings indicated that 33.0% exhibited symptoms based on questionnaires and 35.0% showed objective testing results. The absence of sympathetic skin response was notably 33.6% in MS patients, significantly more frequent compared to healthy controls with an odds ratio of 24.13.
What this does not proveThe evidence regarding the prevalence from objective testing is of very low certainty, meaning the findings should be interpreted cautiously.
A study involving 53 severe progressive multiple sclerosis (MS) patients and matched controls revealed that lower levels of HDL-C, ApoA-I, and ApoA-II, along with higher levels of ApoB and ApoE, were significantly associated with increased disability as measured by the EDSS and CombiWISE scales.
What this does not proveThe study does not establish direct causation, only associations, and the relatively small sample size may limit the general applicability of the results.
The study, involving 160 participants, aimed to compare the pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous administration of Frexalimab in patients with relapsing forms of multiple sclerosis. Participants were monitored over 6 months following their treatment.
What this does not proveNo results have been posted; the study details only describe planned enrollment and endpoints, not findings or outcomes.
In a study of 37 participants, including treatment-naïve relapsing MS patients and healthy controls, researchers found altered tissue microstructure in MS patients compared to controls. After three months of high-efficacy therapy, lesions showed increased fiber ratios but reduced cell ratios in gray matter and lesions.
What this does not proveThis study does not establish long-term treatment efficacy or its applicability beyond the specific cohorts involved.
A study involving 36 patients with multiple sclerosis (MS) and normal pressure hydrocephalus (NPH) found that gait disorders were common, with 83% experiencing bladder dysfunction and 67% cognitive dysfunction. Following ventriculoperitoneal shunt surgery, 58% showed gait improvement post-high-volume tap test, and 83% improved post-surgery.
What this does not proveThe retrospective nature of the study limits the ability to establish causation, and the small sample size may affect the generalizability of the results.
In a retrospective cohort study of 451 MS patients receiving ocrelizumab, the average annualized relapse rate (ARR) decreased by 87%, and 59% achieved No Evidence of Disease Activity (NEDA-3) at Year 1. The study reported a 24-week confirmed disability worsening of 8.9% at 36 months and a persistence rate of 90.7%. Safety findings included infusion reactions in 18.4% and 1.0% with opportunistic infections.
What this does not proveLimitations include the lack of control, potential selection bias, and the fact that the cohort was mildly affected at treatment initiation. Real-world evidence specifically from the MENA region is still limited.
A survey of 5,913 MS patients revealed a mean utility score of 0.576. The highest scores were for relapsing-remitting MS at 0.667, while secondary progressive MS had the lowest at 0.385. Total MS-related costs over three months averaged £2807, with costs ranging widely based on disability status (EDSS).
What this does not proveThe study does not establish causal relationships and does not fully explore variability related to age, sex, MS types, and EDSS scores beyond reported data.
In a study of 240 individuals (123 MS patients and 117 healthy controls), CHI3L1 rs871799 was significantly associated with MS susceptibility, with the CG + GG genotypes more frequent in MS patients. Differences in genotype distributions were found between relapse-remitting MS (RRMS) and progressive forms of MS, suggesting a correlation with clinical phenotype and neurological disability.
What this does not proveThe results are exploratory and must be interpreted with caution due to a small number of progressive MS patients and the combination of SPMS and PPMS in the analysis. Additionally, a cross-sectional assessment limits insight into the progression of disability over time.
Research summaries are for information, not medical advice. Always consult your MS team before changing treatment.
Help us understand how PulseMS is used
With your permission, Google Analytics uses cookies to measure visits and interactions with research. It does not receive your email, account details or community posts. You can change your choice in the footer. Privacy details